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Figure 1. TMA trend in pediatric HSCT recipients
Figure 2
Demographics, risk factors and outcome of patients with TMA
Variable Overall No TMA TMA p
12369 12276 93
Age 0 e 1 years 1948 (15.7) 1939 (99.5) 9 (0.5) 0.109
2 e 4 years 2819 (22.8) 2793 (99.1) 26 (0.9)
5 e 9 years 2775 (22.4) 2758 (99.4) 17 (0.6)
10 e 14
years
2339 (18.9) 2314 (98.9) 25 (l.1)
 15 years 2488 (20.1) 2472 (99.4) 16 (0.6)
Sex Male 7239 (58.5) 7187 (99.3) 52 (0.7) 0.608
Female 5130 (41.5) 5089 (99.2) 41 (0.8)
Race Non-
Hispanic
White
6974 (56.4) 6914 (99.1) 60 (0.9) 0.265
Non-
Hispanic
Black
1450 (11.7) 1445 (99.7) 5 (0.3)
Hispanic 2304 (18.6) 2290 (99.4) 14 (0.6)
Asian 432 (3.5) 428 (99.1) 4 (0.9)
Other 1209 (9.8) 1199 (99.2) 10 (0.8)
Other 7560 (61.1) 7494 (99.1) 66 (0.9)
HSCT Type Autologous 4043 (32.7) 4031 (32.8) 12 (12.9) <.001
Allogeneic 8177 (66.1) 8099 (66) 78 (83.9)
Not speciﬁed 149 (1.2) 146 (1.2) 3 (3.2)
Allo Source Bone
Marrow
3517 (43) 3492 (43.1) 25 (32.1) 0.045
Peripheral
blood
3195 (39) 3154 (38.9) 41 (52.6)
Cord blood 1475 (18) 1463 (18) 12 (15.4)
CMV 958 (7.7) 940 (7.7) 18 (19.4) <.001
HHV6 138 (1.1) 130 (1.1) 8 (8.6) <.001
Fungal
infection
835 (6.8) 814 (6.6) 21 (22.6) <.001
GVHD 1471 (11.9) 1443 (11.8) 28 (30.1) <.001
VOD 227 (1.8) 222 (1.8) 5 (5.4) 0.011
Abstracts / Biol Blood Marrow Transplant 20 (2014) S72eS90S80(CR3), induction failure (IF) or refractory relapse (RR) have
a poor prognosis. (Gaynon, BJH 2005, Wells, JCO 2003,
Hochster/Cairo, BJH 2013) Clofarabine (CLO), a purine anti-
metabolite, has been shown to have synergy with cytarabine
(Faderl, Blood 2005) and induce lasting remissions following
CLO and busulfan-based conditioning and allogeneic he-
matopoietic cell transplantation (AlloHCT) in poor-risk AML.
(Magneau, Blood 2011).
Objectives: This study seeks to determine the safety, day-
100 treatment-related mortality (TRM), and relapse rate
associated with a conditioning regimen of CLO, cytarabine,
and Total Body Irradiation (TBI) followed by AlloHCT in CAYA
with poor-risk ALL or AML.
Methods: This is a multi-center Phase I/II trial of a novel
conditioning regiment of CLO (maximal dose 52mg/m2/
d achieved without dose limiting toxicity) x5d, cytarabine
1000 mg/m2 x6d 4 hours post-CLO, and TBI (1200cGy)
followed by AlloHCT from matched related or unrelated
donors in CAYA with ALL or AML in CR3, RR or IF. GVHD
prophylaxis consisted of tacrolimus and MMF. (Oswunko/
Cairo, BBMT 2004, Bhatia/Cairo, BBMT 2010) Supportive
care consisted of growth factor support, and CMV and
fungal prophylaxis as previously described. (Waxman/
Cairo, Ped. Transplantation 2009, Shereck/Cairo, Ped. Blood
Cancer 2007, Roman/Cairo, Ped. Blood Cancer 2008) Donor
chimerism was assessed by semi-quantitative PCR-based
methods as previously described. (Geyer/Cairo, BJH 2011)
The Kaplan-Meier method was used to determine the
probabilities of engraftment, GVHD, TRM, and overall sur-
vival (OS).
Results: 30 patients, median age: 11.9 yrs (range 1.5 e
21.8); M:F 21:9, ALL:AML 27:3 (10 CR3, 3RR, 17 IF), 11
related donors, 19 unrelated donors (11 BM/PBSCs, 8 UCB).
Median TNC and CD34 dose was 4.49x108/kg and 4.2x106/
kg for BM/PBSCs and 4.8x107/kg and 3.4x105/kg for UCB.
Probabilities of neutrophil, platelet engraftment, grade II-
IV aGVHD and chronic GVHD were 100%, 93%, 47%, and
35% respectively. Median Day 100, 180, and 365 whole
blood chimerisms were all 100%. Day 100 TRM was only
6.7%. The probabilities of relapse, 1-yr progression-free
survival and OS were 27% (CI95: 13-52%), 40% (CI95: 23-
57%), and 47% (CI95: 28-63%) respectively in this poor-risk
population.
Conclusions: These preliminary results suggest that this
novel conditioning regimen including CLO dose 52 mg/m2
with Ara-C and TBI followed by AlloHCT is safe and tolerated
in CAYAwith poor-risk ALL or AML. Our results are promising
with respect to a low risk of day 100 TRM and relapse rate in
this poor risk population. This approach should be consid-
ered in better risk CAYA patients with ALL/AML who require
AlloHCT.Hypertension 3288 (26.6) 3226 (26.3) 62 (66.7) <.001
Renal failure 1280 (10.3) 1232 (10) 48 (51.6) <.001
Plasmapheresis 119 (1) 91 (0.7) 28 (30.1) <.001
Hemodialysis 385 (3.1) 363 (3) 22 (23.7) <.001
Died 1531 (12.4) 1503 (12.2) 28 (30.1) <.00185
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Introduction: Thrombotic microangiopathy (TMA) is a
rare but serious complication of hematopoietic stem cell
transplantation (HSCT). Review of literature showsvariable incidence of TMA following HSCT with high
mortality but its true incidence and outcome in the pe-
diatric population is not known. The purpose of our study
is to estimate the incidence, prevalence and analyze the
risk factors and outcome of TMA in children receiving
HSCT.
Figure 3A. Overall mortality in HSCT recipients. 3B. Mortailty among patients with TMA
Abstracts / Biol Blood Marrow Transplant 20 (2014) S72eS90 S81Methods: We used the Pediatric Health Information Sys-
tem (PHIS), an electronic database of children’s hospitals
in the US. Patients under the age of 21 who underwent
HSCT at one of the 42 PHIS hospitals from 2000-2012 were
analyzed. We abstracted data on demographics, hospital-
izations, TMA and other HSCT related complications.
Results: From 2000 to 2012, a total of 12369 unique pedi-
atric patients who received HSCT were identiﬁed. Among
these 93 (0.8%) children were identiﬁed to have the diag-
nosis of TMA. Overall, there was an increasing trend of TMA
diagnosis seen in our cohort (Figure 1). The demographic
characteristics, risk factors and outcome of these children
with and without TMA are shown in Figure 2. TMA was
signiﬁcantly associated with allogeneic HSCT (p¼<0.001),
PBSCT (p¼0.045), CMV (p¼<0.001), HHV6 (p¼<0.001),
fungal infection (p¼<0.001), GVHD (p¼<0.001) and VOD
(p¼0.01). The mortality was signiﬁcantly higher in patients
with TMA compared to those without (30.1% vs. 12.2%,
p¼<0.001, Figure 3A). Also, median time (days) to mor-
tality following HSCT was shorter in patients with TMA
than those without (754 [365, 1614] vs. 1439 [552, 2847],
p¼<0.0001). Multivariate logistic regression analysis of
mortality using age, gender, HSCT type, CMV, HHV6, fungal
infection and plasmapheresis showed only HHV6 was an
independent risk factor associated with increased mortal-
ity in patients with TMA (Hazard Ratio: 2.86 [1.01, 8.39],
p¼0.05) (Figure 3B).
Conclusions: Ours is the largest cohort of TMA following
HSCT in children. The prevalence of TMA in our study is
0.8% with an increasing trend in recent years. The mortality
in our pediatric TMA cohort is 30% which is in contrast to
the higher mortality reported in previously published
small case series. HHV6 emerged as not only a risk factor
for TMA but also associated with increased mortality in
these patients. Plasmapheresis was not associated with
improved survival in our study. Studies exploring the
pathophysiology of TMA and its relationship to other
complications of HSCT are needed to optimize the out-
come.86
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Allogenic stem cell transplantation is the only curative op-
tion for patients with inherited bone marrow failure syn-
drome such as congenital amegakaryocytic thrombopenia
disease (CAMT). This multicenter retrospective study is
based on data reported to the EBMT registry on patients with
CAMT who underwent allogeneic hematopoietic stem cell
transplantation from 1987 to 2013. Sixty three patients with
CAMT were transplanted with identical sibling donor
(n¼25), matched unrelated donor (n¼25), matched other
relative (n¼5) and mismatched donor (n¼8). Stem cell
source were bone marrow (n¼31) or peripherical blood
(n¼21) or cord blood (n¼11). Age at HSCT varied from 6
months to seventeen years. Conditioning regimen was
available for 50 patients : 41 (82%) patients received mye-
loablative conditioning regimen and 9 (18%) patients
reduced intensity one. The median time for neutrophil re-
covery was nineteen days. Cumulative incidence of grade II-
IV aGvHD was 13%. Cumulative incidence of chronic exten-
sive GvHD was 6.3%. 5 year-overall survival was 76.6%+/-7
and TRM is 12.6%+/-4 with no difference by age, gender, year
of transplant, HLA compatibility and stem cell source. 53
(84%) patients were alive at last follow up. Nine patients
(14.3%) died, seven from HSCT, one from disease and two
from other causes. Eleven patients underwent second HSCT
and six patients third HSCT. From them, four patients died
and seven were alive, six were free of disease and one still
with CAMT. This study is the wider reported so far and
conﬁrms that CAMT in children can successfully be treated
by allogenic stem cell transplantation. Patients who lack a
